FDA Approves Lower Dose of Adapt Pharma’s Overdose Therapy Narcan

The FDA approved a 2-mg formulation of Adapt Pharma’s nasal spray Narcan to treat a known or suspected opioid overdose.

The dose is indicated for opioid-dependent patients expected to be at risk for severe opioid withdrawal, the company said.

In November 2015, Adapt received approval for a 4-mg formulation of Narcan as the first nasal spray version of naloxone hydrochloride.